GRAIL completed the $390m Series D funding round.

Public Sector Pension Investment Board and Canada Pension Plan Investment Board invested $390m Series D funding round in GRAIL, a biotechnology company. “GRAIL is making significant progress with our blood-based, multi-cancer early detection test. Nearly 80 percent of cancer deaths result from cancers for which there is no screening test today, and GRAIL’s mission is to change that through the early detection and localization of more than 50 cancers. Enabling this through a single blood draw could improve patient access and adherence to cancer screening and address disparities in cancer care by improving access for rural, vulnerable, and under-served populations. We are delighted that such a high-quality group of investors share our vision and recognize the public health benefits of our technology," Hans Bishop, GRAIL Chief Executive Officer.